Okomera specializes in advanced automated 3D organoid screening technology that significantly enhances the drug discovery process. Their platform integrates standard assays, such as CRISPR and T-cell cytotoxicity tests, allowing for the rapid validation of drug targets and improving the predictability of preclinical studies. The technology is designed for high throughput, enabling the simultaneous testing of over 800 conditions across 1,000 microtumors, which is a substantial increase in efficiency compared to traditional methods. This approach not only minimizes the required patient sample size—using 1,000 times less than competitors—but also accelerates the turnaround time to approximately one week, making it accessible without the need for specialized lab expertise.

The innovative design of Okomera's technology emphasizes miniaturization and automation, which are crucial for modernizing drug discovery. By utilizing microfluidic systems, the company can conduct multiplexed assays that streamline the testing process and facilitate personalized medicine. This capability allows researchers to explore diverse and impactful use cases, including drug screening and evaluating immune responses in relevant microenvironments. Overall, Okomera's advancements represent a significant leap forward in the efficiency and effectiveness of preclinical drug development.

France

We integrate standard assays on chip (eg. CRISPR, T-cell, cytotoxicity) to accelerate drug discovery from target to validation, and advance preclinical predictivity

Okomera

Company Details